Cargando…

Combined BRD4 and CDK9 inhibition as a new therapeutic approach in malignant rhabdoid tumors

Rhabdoid tumors are caused by the deletion of SMARCB1, whose protein encodes the SMARCB1 subunit of the chromatin remodeling complex SWI/SNF that is involved in global chromatin organization and gene expression control. Simultaneously inhibiting the main players involved in the deregulated transcrip...

Descripción completa

Detalles Bibliográficos
Autores principales: Moreno, Natalia, Holsten, Till, Mertins, Julius, Zhogbi, Annabelle, Johann, Pascal, Kool, Marcel, Meisterernst, Michael, Kerl, Kornelius
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5689588/
https://www.ncbi.nlm.nih.gov/pubmed/29156698
http://dx.doi.org/10.18632/oncotarget.18583
_version_ 1783279411110346752
author Moreno, Natalia
Holsten, Till
Mertins, Julius
Zhogbi, Annabelle
Johann, Pascal
Kool, Marcel
Meisterernst, Michael
Kerl, Kornelius
author_facet Moreno, Natalia
Holsten, Till
Mertins, Julius
Zhogbi, Annabelle
Johann, Pascal
Kool, Marcel
Meisterernst, Michael
Kerl, Kornelius
author_sort Moreno, Natalia
collection PubMed
description Rhabdoid tumors are caused by the deletion of SMARCB1, whose protein encodes the SMARCB1 subunit of the chromatin remodeling complex SWI/SNF that is involved in global chromatin organization and gene expression control. Simultaneously inhibiting the main players involved in the deregulated transcription machinery is a promising option for preventing exaggerated tumor cell proliferation and survival as it may bypass compensatory mechanisms. In support of this hypothesis, we report efficient impairment of cellular proliferation and strong induction of cell death elicited by inhibition of bromodomain protein BRD4 and transcription kinase CDK9 using small molecular compounds. Combination of both compounds efficiently represses antiapoptotic genes and the oncogene MYC. Our results provide a novel approach for the treatment of RT.
format Online
Article
Text
id pubmed-5689588
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-56895882017-11-17 Combined BRD4 and CDK9 inhibition as a new therapeutic approach in malignant rhabdoid tumors Moreno, Natalia Holsten, Till Mertins, Julius Zhogbi, Annabelle Johann, Pascal Kool, Marcel Meisterernst, Michael Kerl, Kornelius Oncotarget Research Paper Rhabdoid tumors are caused by the deletion of SMARCB1, whose protein encodes the SMARCB1 subunit of the chromatin remodeling complex SWI/SNF that is involved in global chromatin organization and gene expression control. Simultaneously inhibiting the main players involved in the deregulated transcription machinery is a promising option for preventing exaggerated tumor cell proliferation and survival as it may bypass compensatory mechanisms. In support of this hypothesis, we report efficient impairment of cellular proliferation and strong induction of cell death elicited by inhibition of bromodomain protein BRD4 and transcription kinase CDK9 using small molecular compounds. Combination of both compounds efficiently represses antiapoptotic genes and the oncogene MYC. Our results provide a novel approach for the treatment of RT. Impact Journals LLC 2017-06-21 /pmc/articles/PMC5689588/ /pubmed/29156698 http://dx.doi.org/10.18632/oncotarget.18583 Text en Copyright: © 2017 Moreno et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Moreno, Natalia
Holsten, Till
Mertins, Julius
Zhogbi, Annabelle
Johann, Pascal
Kool, Marcel
Meisterernst, Michael
Kerl, Kornelius
Combined BRD4 and CDK9 inhibition as a new therapeutic approach in malignant rhabdoid tumors
title Combined BRD4 and CDK9 inhibition as a new therapeutic approach in malignant rhabdoid tumors
title_full Combined BRD4 and CDK9 inhibition as a new therapeutic approach in malignant rhabdoid tumors
title_fullStr Combined BRD4 and CDK9 inhibition as a new therapeutic approach in malignant rhabdoid tumors
title_full_unstemmed Combined BRD4 and CDK9 inhibition as a new therapeutic approach in malignant rhabdoid tumors
title_short Combined BRD4 and CDK9 inhibition as a new therapeutic approach in malignant rhabdoid tumors
title_sort combined brd4 and cdk9 inhibition as a new therapeutic approach in malignant rhabdoid tumors
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5689588/
https://www.ncbi.nlm.nih.gov/pubmed/29156698
http://dx.doi.org/10.18632/oncotarget.18583
work_keys_str_mv AT morenonatalia combinedbrd4andcdk9inhibitionasanewtherapeuticapproachinmalignantrhabdoidtumors
AT holstentill combinedbrd4andcdk9inhibitionasanewtherapeuticapproachinmalignantrhabdoidtumors
AT mertinsjulius combinedbrd4andcdk9inhibitionasanewtherapeuticapproachinmalignantrhabdoidtumors
AT zhogbiannabelle combinedbrd4andcdk9inhibitionasanewtherapeuticapproachinmalignantrhabdoidtumors
AT johannpascal combinedbrd4andcdk9inhibitionasanewtherapeuticapproachinmalignantrhabdoidtumors
AT koolmarcel combinedbrd4andcdk9inhibitionasanewtherapeuticapproachinmalignantrhabdoidtumors
AT meisterernstmichael combinedbrd4andcdk9inhibitionasanewtherapeuticapproachinmalignantrhabdoidtumors
AT kerlkornelius combinedbrd4andcdk9inhibitionasanewtherapeuticapproachinmalignantrhabdoidtumors